To test this hypothesis, we examined a well-studied paradigm of enhancer-mediated oncogene expression in AML: the regulation of Myc through its AML-specific superenhancer cluster, the Blood Enhancer Cluster (BENC). The gene discussed is MYC; the disease is acute myeloid leukemia.